Risk and management of congenital thrombophilia in transgender individuals undergoing gender-affirming hormone therapy
{{output}}
Background: Gender-affirming hormone therapy (GAHT), particularly estrogen-based regimens, is associated with an increased risk of venous thromboembolic events (VTE), which may be exacerbated in individuals with hereditary thromb... ...
